NCT04643275 is a NA clinical trial of BTL-899 in Fat Burn, sponsored by BTL Industries Ltd..

Who is sponsoring NCT04643275?

NCT04643275 is sponsored by BTL Industries Ltd..

What drugs are being tested in NCT04643275?

Interventions in NCT04643275: BTL-899.

Is NCT04643275 still recruiting?

NCT04643275 is currently completed. Last updated 9 September 2021.

Last reviewed 2021-09-09 · How we verify

NCT04643275

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of BTL-899 Device for Non-invasive Lipolysis on Human Upper Arms

Completed NA Last updated 9 September 2021

What this trial tests

NA trial testing BTL-899 in Fat Burn in 45 participants. Completed in 2 September 2021.

Timeline

15 October 2020

Primary endpoint
2 August 2021

2 September 2021

Quick facts

Lead sponsor	BTL Industries Ltd.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	15 October 2020
Primary completion	2 August 2021
Estimated completion	2 September 2021
Sites	1 location across Bulgaria

Drugs / interventions tested

BTL-899

Conditions studied

Fat Burn — all drugs for Fat Burn →

Sponsor

BTL Industries Ltd. — full company profile →

Who can join

Adults 21 to 70, any sex, with Fat Burn. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the clinical safety and the performance of the BTL-899 device during the treatment of upper arms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of BTL-899

Trials testing the same drug.

NCT05540080 — Non-invasive Lipolysis and Improvement of Muscle Tone in Lateral Abdomen · NA · completed
NCT05713864 — Combination Treatment With BTL-899 and HPM-6000UF Devices II · NA · completed
NCT05139745 — Histological Evaluation of BTL-899 Device´s Effect on Fat Tissue · NA · completed
NCT04596228 — Non-invasive Lipolysis and Improvement of Muscle Tone in Inner Thighs · NA · completed
NCT04596241 — Non-invasive Lipolysis and Improvement of Muscle Tone in Upper Arms · NA · completed

Other recruiting trials for Fat Burn

Currently open trials in the same condition.

NCT06763562 — Food Orders on Blood Glucose and Fuel Use At Rest · NA · recruiting

Other BTL Industries Ltd. trials

Trials by the same sponsor.

NCT07413692 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and E · NA · recruiting
NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and · NA · recruiting
NCT07179224 — EEG Changes After rTMS Stimulation · NA · completed
NCT07024550 — Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway · NA · active not recruiting
NCT07027657 — EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04643275 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BTL Industries Ltd.
Last refreshed: 9 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04643275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing